Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acromegaly is mainly due to the somatotroph pituitary neuroendocrine tumors (PitNET)s. These have been subtyped into densely granulated (DG) and sparsely granulated (SG) tumors, which differ in clinical, histological and biological characteristics and in response to somatostatin analogs (SA)s. The variable remission rate after surgical resection, as first line treatment, has increased interest in identifying pathological markers to better predict the response to medical treatment.
|
30531694 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Little data is available regarding the safety and efficacy of switching to Pasireotide-LAR monotherapy in acromegaly patients with partial resistance to first generation somatostatin agonists (1gSRL) who require combination treatment with cabergoline or pegvisomant.
|
31518993 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections.
|
31522359 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly.
|
30826981 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.
|
30506213 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review.
|
31143230 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin analogs are the gold standard of medical therapy; however, resistance represents a big drawback in acromegaly management.
|
30986651 |
2019 |
Acromegaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this paper a literature review was conducted for information related to costs of management of acromegaly and its associated comorbidities using PubMed.The majority of total costs represent pharmacological treatment, especially the most common somatostatin analogues (SSA) therapy.
|
30843180 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing's disease (CD).
|
30483918 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies.
|
31575930 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing's disease and acromegaly.
|
31212595 |
2019 |
Acromegaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is no study investigating the impact of somatostatin analog (SSA) treatment on thyroid nodule volume in patients with acromegaly.
|
30745501 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Postoperative use of somatostatin analogs and mortality in patients with acromegaly.
|
30400068 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.
|
30122081 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
The patient refused pituitary surgery, and her acromegaly is currently well-controlled with somatostatin analogue therapy.
|
30742299 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment for acromegaly.
|
30608534 |
2019 |
Acromegaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aryl hydrocarbon receptor interacting protein (AIP) mutations are associated with an aggressive, inheritable form of acromegaly that responds poorly to SST2-specific somatostatin analogs (SSA).
|
30851160 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
|
30285115 |
2019 |
Acromegaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we assessed the contribution of GSTP1 gene promoter methylation status, per se or in combination with the occurrence of the AHR gene rs2066853 variant, on clinical features and response to somatostatin analogs (SSA) treatment in acromegaly patients.
|
30488289 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with available synthetic somatostatin analogues (SSAs) is considered the mainstay in the medical management of acromegaly which exert their beneficial effects through the binding to a family of G-protein coupled receptors encoded by 5 genes (SSTR1-5).
|
30650942 |
2019 |
Acromegaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 43-year-old patient was diagnosed with an acromegaly due to a GH-secreting pituitary microadenoma resistant to somatostatin analogs.
|
31264077 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erratum to "Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study".
|
30962806 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-acting repeatable (LAR) octreotide i.m. is a potent, synthetic somatostatin analogue (SSA) that requires less frequent dosing and offers quality of life (QoL) benefits in acromegaly patients compared to its shorter-acting predecessor.
|
31274183 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
|
30718563 |
2019 |
Acromegaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pegvisomant (PEG) in monotherapy or combined with somatostatin analogs (SSAs) is used to control acromegaly, improving metabolism.
|
30869797 |
2019 |